Australia based Aravax, which is using a peptide based approach to food allergy treatments with the goal of avoiding inflammation, is building out late stage manufacturing capabilities in Oxford, UK

CEO Pascal Hickey introduces us to the company and describes the scale up work Aravax is doing with vendors for its lead peanut allergy program, while CSO Sara Prickett explains how the peptide approach aims to teach T-cells to correct allergies while not setting off allergic inflammation that today's therapies do.